Tablet PK exposure increases proportionally with an increase in dose More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced variability Tablet steady state...Read more
PIPE-307 demonstrated an acceptable safety and tolerability profile PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter acuity (LCLA) SAN DIEGO / Nov 20, 2025 / Business Wire / Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or...Read more
CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,...Read more
EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First U.S. Food and Drug Administration Emergency Use Authorization (EUA) granted for New World screwworm in cats, reinforcing Elanco's leadership in...Read more
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with muscle-invasive bladder cancer Approval is based on unprecedented data from the pivotal...Read more
Represents the first PD-1 inhibitor plus ADC regimens for this patient population RAHWAY, N.J. / Nov 21, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®...Read more
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Mettler-Toledo | 52.94 3.78 | $1,452.35 |
| IDEXX Laboratories | 36.56 5.30 | $725.91 |
| Regeneron Pharmaceuticals | 18.90 2.56 | $755.90 |
| Insulet | 18.28 5.84 | $331.17 |
| McKesson | 16.57 1.95 | $866.03 |
| Eli Lilly | 16.41 1.57 | $1,059.70 |
| Waters | 15.37 4.06 | $393.99 |
| Thermo Fisher Scientific | 14.74 2.57 | $587.48 |
| HCA Healthcare | 14.72 3.09 | $491.00 |
| West Pharmaceutical | 13.30 5.16 | $271.07 |
| Bio-Rad Laboratories | 13.09 4.31 | $316.70 |
| GeneDx | 12.46 9.29 | $146.55 |
| Chemed | 12.41 2.89 | $441.74 |
| Belite Bio | 10.82 9.86 | $120.56 |
| Intuitive | 9.38 1.70 | $561.61 |
| Penumbra | 8.68 3.10 | $288.47 |
| Monopar Therapeutics | 8.56 10.31 | $91.56 |
| Cigna | 8.49 3.15 | $278.09 |
| Company | Volume | Last Trade |
|---|---|---|
| Sangamo Therapeutics | 428,102,863 | $0.43 |
| Recursion | 81,693,582 | $4.17 |
| Pfizer | 71,039,657 | $25.03 |
| Incannex Healthcare | 62,560,466 | $0.32 |
| Mobile-health Network Solutions | 60,546,843 | $4.91 |
| PacBio | 49,562,648 | $2.22 |
| Exact Sciences | 36,179,836 | $100.94 |
| Telomir Pharmaceuticals | 27,960,392 | $1.28 |
| Geron | 25,113,897 | $1.12 |
| Applied Therapeutics | 22,579,382 | $0.26 |
| Humacyte | 22,482,056 | $1.22 |
| agilon health | 22,277,424 | $0.63 |
| Merck | 21,533,274 | $97.76 |
| Novo Nordisk | 18,881,743 | $47.65 |
| BioAtla | 18,693,837 | $0.91 |
| HeartBeam | 17,442,085 | $0.77 |
| Moderna | 17,213,555 | $23.72 |
| Iovance Biotherapeutics | 16,562,971 | $2.24 |
| ImmunityBio | 16,079,512 | $2.08 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
